Amended Claims

Claims 1-7 (canceled).

8. **(currently amended)** A compound; an isomer of the compound, enantiomer of the compound, tautomer of the compound, racemate of the compound, or polymorph of the compound; or a pharmaceutically-acceptable salt of the compound, isomer, enantiomer, tautomer, or racemate, wherein:

the compound corresponds in structure to Formula I:



I;

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, S, SO, CH(OH), and SO_2;

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatoms selected from the group consisting of O, S, and N;

Z_1-Z_2 optionally further contains a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, or acyl;

the carbon and nitrogen atoms of Z_1-Z_2 are optionally substituted by a substituent selected from the group consisting of alkyl, alkoxy, alkylthio, alkylsulfone, aryl, alkoxyalkyl, alkylamino, heteroaryl, hydroxyl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

each n is selected from the group consisting of zero, 1, and 2;

R^c is selected from the group consisting of hydrogen, alkyl, halogen, hydroxyl, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, alkylthio, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and $-(CH_2)_n$-COR;

R is selected from the group consisting of hydroxyl, alkoxy, alkyl, and amino;

X is selected from the group consisting of O, CO, SO_2, NR^m, and $(CHR^p)_n$;

R^p and R^m are H or alkyl;

X_3 is selected from the group consisting of O, S, and NR^j;

R^h and R^j are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl, and alkoxyalkyl; and

A^1 is selected from the group consisting of:



,



,


,



,



,



,


,



,










































,


,


,


,


,


,


,


,


,


,


,


,


























,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
































,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,















,


,


,


,


,


,


,


,




,




,











































































9. **(previously presented)** A compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt according to claim 8, wherein said compound is 1,2,3,4-tetrahydro-1-oxo-[6-[3-(2-tetrahydropyrimidinyl)amino]-propoxy]-2-isoquinolineacetic acid.

10. **(previously presented)** A pharmaceutical composition, wherein the composition comprises:

a compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt of claim 8 in an amount that is effective to inhibit or antagonize $\alpha_v\beta_3$ or $\alpha_v\beta_5$; and

a pharmaceutically acceptable carrier.

11. **(currently amended)** A method for treating a condition mediated by the $\alpha_v\beta_3$ integrin in a mammal, wherein:

the condition is selected from the group consisting of ~~**tumor metastasis, tumor growth, solid tumor growth, angiogenesis,**~~ osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy, and arthritis; and the method comprises administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt of claim 8.

Claim 12. (canceled).

13. **(currently amended)** A method for treating a condition mediated by the $\alpha_v\beta_5$ integrin in a mammal, wherein:

the condition is selected from the group consisting of ~~**tumor metastasis, tumor growth, solid tumor growth, angiogenesis,**~~ osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy, and arthritis; and

the method comprises administering an effective $\alpha_v\beta_5$ inhibiting amount of a compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt of claim 8.

Claims 14-16 (canceled).